Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Dow
UBS
Cantor Fitzgerald
Mallinckrodt
Colorcon
Fuji
Accenture
McKesson

Generated: July 18, 2018

DrugPatentWatch Database Preview

Sun Pharm Inds Company Profile

« Back to Dashboard

What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?

SUN PHARM INDS has two hundred and twenty-eight approved drugs.

There are thirteen US patents protecting SUN PHARM INDS drugs. There are four tentative approvals on SUN PHARM INDS drugs.

There are forty-one patent family members on SUN PHARM INDS drugs in twenty-three countries and one hundred and sixty-nine supplementary protection certificates in thirteen countries.

Summary for Sun Pharm Inds
International Patents:41
US Patents:13
Tradenames:167
Ingredients:156
NDAs:228

Drugs and US Patents for Sun Pharm Inds

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd LIOTHYRONINE SODIUM liothyronine sodium TABLET;ORAL 091382-001 Apr 20, 2016 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Inc PAROXETINE HYDROCHLORIDE paroxetine hydrochloride TABLET;ORAL 078194-004 Jun 29, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Inc BACLOFEN baclofen TABLET;ORAL 077862-002 Aug 14, 2006 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd LISINOPRIL lisinopril TABLET;ORAL 075944-002 Jul 1, 2002 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sun Pharm Inds

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate OINTMENT;TOPICAL 019968-001 Dec 17, 1990 4,619,921 ➤ Try a Free Trial
Sun Pharm Inds Inc EXELDERM sulconazole nitrate SOLUTION;TOPICAL 018738-001 Aug 30, 1985 4,055,652 ➤ Try a Free Trial
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 4,619,921 ➤ Try a Free Trial
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 5,908,838 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SUN PHARM INDS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 30 mg and 40 mg ➤ Subscribe 2012-12-31
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-06-19
➤ Subscribe Capsules 25 mg ➤ Subscribe 2016-05-16
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-01-07
➤ Subscribe Capsules 35 mg ➤ Subscribe 2015-11-25

Non-Orange Book US Patents for Sun Pharm Inds

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,559,187 Liquid formulation of metformin ➤ Try a Free Trial
9,192,615 Method for the treatment of acne and certain dosage forms thereof ➤ Try a Free Trial
8,722,650 Extended-release minocycline dosage forms ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Sun Pharm Inds Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2002 Austria ➤ Try a Free Trial PRODUCT NAME: ESCITALOPRAM UND DESSEN NICHT-TOXISCHE SAEUREADDITIONSSALZE; NAT. REGISTRATION NO/DATE: 1-24549, 1-24550, 1-24551, 1-24552 20020618; FIRST REGISTRATION: SE 17084, 17085, 17086,17087 20011207
80045 Netherlands ➤ Try a Free Trial PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
00524 Netherlands ➤ Try a Free Trial PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
00357 Netherlands ➤ Try a Free Trial PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
Dow
Fuji
Accenture
Julphar
Deloitte
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.